PubMed · 13028439
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R WORMS, H PEQUIGNOT, J CIVATTE. 1952-11-06. [Does hepatic anergy exist?].. https://pubmed.ncbi.nlm.nih.gov/13028439/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
In order to apply for reducing graft versus host disease in allogeneic stem cell transplantation, the study concerning the induction of specific T cell anergy was designed. Normal allogeneic lymphocytes, which were co-cultured with IL-10-treated immature dendritic cells in the first mixed leukocyte culture (MLC), were cultured with mature dendritic cells of the same origin as IL-10-treated immature dendritic cells in the second MLC. By co-culturing with IL-10-treated immature dendritic cells, the response of normal lymphocytes to mature dendritic cells cultured from the same individual as that of IL-10-treated dendritic cells was markedly reduced, compared with the lymphocytes cultured with non-treated dendritic cells or IL-10-treated dendritic cells from a third party individual. The present study demonstrated that antigen specific T cell anergy was generated by priming allogeneic lymphocytes with IL-10-treated immature dendritic cells. These data suggested the applicability of IL-10-treated recipient dendritic cells for the induction of recipient cell-specific donor T cell anergy in donor graft.
Mortality among critically ill patients has been attributed to the development of sepsis. About 28% of patients with sepsis still die, despite numerous interventions. Trials on sepsis investigated mostly anti-inflammatory strategies, based on the prevailing theory that sepsis represents an uncontrolled inflammatory response. None of these showed convincing benefit in humans, despite promising results in animal studies. The reason for this is becoming clear: sepsis represents a biphasic response to infection, and the initial pro-inflammatory response that we have targeted thus far is invariably followed by a prolonged period of immune suppression. In addition, a patient may oscillate between a pro- and anti-inflammatory state repeatedly. A single magic bullet therapy is thus unlikely to work. The mediators of this process are the cytokines, and a lot of research is focussed on modulating these to achieve a better outcome. In addition, the central role of the coagulation cascade in mediating inflammation and sepsis is becoming clear, and therapies addressing this mechanism are promising.
Explore the source record for details and available documents.